In yesterday’s decision, the panel agreed with the district court that, during prosecution of the patent, Amgen “clearly and unmistakably surrendered salt combinations other than the particular combinations recited in the claims,” and that prosecution history estoppel bars Amgen from succeeding on its infringement claims under the doctrine of equivalents.
Yesterday, Amgen lost its fight to block Coherus BioSciences from selling its biosimilar pegfilgrastim, Udenyca, referencing Amgen’s innovator drug, Neulasta. A 3-judge panel of the US Court of Appeals for the Federal Circuit affirmed a decision that, in 2018, dismissed Amgen’s case.
Amgen holds a patent, US patent 8,273,707, on methods of purifying proteins in which specific salts are used in a loading solution. When Coherus filed an abbreviated Biologics License Application (aBLA) for its biosimilar pegfilgrastim, the aBLA revealed that Coherus’ manufacturing process contained steps to purify pegfilgrastim.
One such step involved use of a salt combination in a chromatography buffer, though this combination was not among the specific combinations described in Amgen’s patent. However, Amgen sued Coherus for infringing on its patent under the doctrine of equivalents, a means by which a patent holder can claim infringement even if not all of the elements of the patented invention are identical in the allegedly infringing process.
Coherus moved to dismiss Amgen’s complaint, and a magistrate judge recommended that Coherus’ motion be granted. The district court adopted the magistrate judge’s report and granted Coherus’ motion to dismiss.
In yesterday’s decision, the panel agreed with the district court that, during prosecution of the patent, Amgen “clearly and unmistakably surrendered salt combinations other than the particular combinations recited in the claims,” and that prosecution history estoppel bars Amgen from succeeding on its infringement claims under the doctrine of equivalents.
Thus, according to the decision, “the district court did not err” in its ruling, and the panel affirmed the district court’s decision.
Thomas Fitzpatrick, JD, Coherus’ chief legal officer, said in a statement that “We are pleased by the Federal Circuit’s precedential decision and have always been confident that the District Court’s decision would be affirmed on appeal.” He added, “We are particularly pleased to continue our mission to successfully lower healthcare costs and expand patients’ access to life-saving drugs.”
Coherus launched its pegfilgrastim biosimilar in the United States in January 2019 and recently marked the 6-month anniversary of the product’s launch by revealing that the company has produced more than 400,000 prefilled syringes of the product to date, and by saying that its preliminary unaudited net sales for the product in the last quarter are estimated to be between $79 million and $84 million.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.